Share this article on:

Methicillin-resistant Staphylococcus aureus: a systematic review

Nazari, Mohammad Rezaa; Sekawi, Zamberib; Sadeghifard, Nourkhodaa; Raftari, Mohammadb; Ghafourian, Sobhana

Reviews in Medical Microbiology: January 2015 - Volume 26 - Issue 1 - p 1–7
doi: 10.1097/MRM.0000000000000023
Bacteriology

Staphylococcus aureus is a Gram-positive facultative aerobic, nonmotile coccus that is an opportunistic pathogen in both humans and animals. A new window was opened for eradication of infections by bacteria with the discovery of antibiotics. Plasmid-borne resistance genes appeared soon afterwards. Currently, the distribution of antibiotic-resistant genes between bacteria via horizontal and vertical transformation and prescription of antibiotics has severely complicated treatment of infection. Antibiotic resistant bacteria have become a worldwide concern. Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus are now recognized as problematic bacteria. The current review aims to cover some aspects of MRSA and its distribution worldwide.

aClinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

bDepartment of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia.

Correspondence to Sobhan Ghafourian, PhD, Clinical Microbiology Research Center, Ilam University of Medical Sciences, 6931619 Ilam, Iran. E-mail: sobhanghafurian@yahoo.com

Received 20 April, 2014

Revised 5 September, 2014

Accepted 5 September, 2014

Back to Top | Article Outline

Introduction

Staphylococcus aureus is a Gram-positive coccus, facultative aerobic, and grows as grape-like clusters; it is an opportunistic pathogen for both humans and animals. The most common infections by S. aureus are skin and soft tissue infections, respiratory infections and food poisoning [1].

Back to Top | Article Outline

Carriage of Staphylococcus aureus

Naturally, S. aureus colonizes humans and can be found in the throat, perineum, groin, anterior nares and skin. Nasal carriage of S. aureus is one of the common risk factors causing infections in the community and in hospitals [2,3]. Nasal carriage of S. aureus is associated with infection in patients with underlying diseases including AIDS, insulin-dependent diabetes mellitus, continuous ambulatory peritoneal dialysis and skin diseases [4,5].

Prevalence of S. aureus nasal carriage varies from 9 to 100%, with a mean of 37% [6]. S. aureus nasal carriage rates varied with the age of the human individual [3,6]; there is higher rate of S. aureus nasal carriage among children than among adults. It is more prevalent between the ages of 10 and 20 years [7]. In addition, the rate of S. aureus nasal carriage was found to be higher in boys than in girls and is therefore associated with the hormonal status [8]. Different strains of S. aureus can be found in the colonized individual potentially stimulating the horizontal transfer of antimicrobial-resistant genes [9].

Back to Top | Article Outline

Staphylococcus aureus infections

S. aureus causes many diseases in humans, including skin and soft tissue infections (abscesses, carbuncles, folliculitis, furuncles, impetigo, bullous impetigo and cellulitis), which in the absence of antimicrobial therapy may lead to bloodstream infections and septic shock [10]. Other infections caused by S. aureus include endocarditis, pneumonia, bone and joint infections. S. aureus skin infections are frequent in the United States, Canada, Latin America, Europe and the Western Pacific, although it is isolated from cases of pneumonia and bloodstream infection worldwide [11]. Wound and catheter-related infections are closely associated with S. aureus. One primary cause of nosocomial bacteraemia is associated with intravascular catheter-related infections [12]. Toxin-mediated diseases such as toxic shock syndrome and food poisoning are associated with TSST-1 and enterotoxin-producing S. aureus[13].

Back to Top | Article Outline

Methicillin-resistant Staphylococcus aureus

History of methicillin-resistant Staphylococcus aureus

The 1940s saw the introduction of penicillin, the first antimicrobial agent effective against S. aureus. Subsequently, resistance to penicillin was observed [14] and a plasmid harbouring β-lactamase gene was found to be responsible for creation of penicillin-resistant S. aureus[15]. Penicillin-resistant S. aureus became a worldwide concern during the next two decades. In 1959, methicillin (a semi-synthetic derivative of penicillin and resistant to the β-lactamase enzyme) was used for treatment of infections caused by penicillin-resistant S. aureus. After that, penicillin-resistant S. aureus decreased significantly [16]. The first isolates of methicillin-resistant S. aureus (MRSA) were reported in 1961 [17]. Until the late 1970s, the prevalence of MRSA was considered sporadic, but MRSA was soon observed worldwide [18]. MRSA is now a major cause of morbidity and mortality [19], and increasingly prevalent in many regions [20].

Back to Top | Article Outline

Mechanism of resistance to methicillin in Staphylococcus aureus

Penicillin-binding proteins: the targets of β-lactam antibiotics

Back to Top | Article Outline

Peptidoglycan structure in Staphylococcus aureus

The S. aureus cell wall comprises a very thick layer of peptidoglycan. The structure of the cell wall is a repeat of β1–4-linked N-acetylglucosamine-N-acetylmuramic acid (NAM) with attached teichoic acids [21]. Each NAM is cross-linked to four of five amino acid chains containing L-alanine, D-iso-glutamine, L-lysine and D-alanine with a penta-glycine bridge between L-Lysine and D-alanine (Fig. 1).

The bridge is formed in the cytoplasm by FemX, FemA and FemB proteins that bind the glycine residues to the L-lysine residue of the stem peptides. The cross-linking occurs on the external layer of the cytoplasmic membrane in a reaction catalyzed by penicillin-binding proteins (PBPs). The PBPs are divided into four types, namely PBP1, PBP2, PBP3 and PBP4.

The PBPs have two protein domains, one of the domains is in cross-linking and another in transglycosylation. β-lactam antibiotics such as methicillin and oxacillin bind to the terminal D-alanyl-D-alanine of the stem peptide, thereby inhibiting the first domain of PBPs (transpeptidation) and the initiation of cross-linking. Therefore, the peptidoglycan is unable to crosslink, allowing leakage of cytoplasm outside the cell, resulting in the death of the bacterial cells [22]. MRSA has developed a different foreign PBP called PBP2a (resistant to methicillin).

Back to Top | Article Outline

Penicillin-binding protein 2a

The difference between methicillin-sensitive S. aureus and MRSA is the presence of mecA gene, which encodes a different 78-kDa PBP (PBP2a). The mecA gene is originally from Staphylococcus sciuri[23]. CcrA and B, located in mec element, code a recombinase protein that is responsible for unifying and fission of the mec element into the chromosome [24]. The mec element is highly conserved between different isolates. PBP2a is a motif from the other PBP, which has a low affinity to bind with β-lactam antibiotics. Notably, resistance to methicillin and other β-lactam antibiotics in S. aureus is associated with mobile staphylococcal chromosomal cassettes that harbour the mecA gene and is known as Staphylococcal chromosomal cassettes mecA (SCCmecA) [24].

Back to Top | Article Outline

The ccr gene complex

The ccr gene complex includes the ccr genes and ORFs. S. aureus has three different ccr genes, which are ccrA, B and C. CcrA and B are divided into four different allotypes. Ccr genes, which have more than 85% similarity in their sequences, are classified as the same allotype. The ccrC gene has more than one different allele, ccrC1 allele 2, ccrC1 allele 3. Different ccr have different allotypes; for example, S. aureus type 1 harboured ccrA1B1 and type 2 possesses ccrA2B2 [25].

Back to Top | Article Outline

mecA

As mentioned, mecA is associated with resistance to the β-lactam antibiotics. mecA encodes PBP2a, which is different from the other PBPs [26]. MecI and mecR1 are the regulator genes that control mecA. MecI is the repressor for mecA, while mecR1 plays a different role as a signal for transduction cascade [27]. In addition, mecA is also under control of two corepressors (blaI and blaR1). BlaI is homologous of mecI and blaR1 is similar to mecR1. These two corepressors are responsible for controlling blaZ that is responsible for penicillin resistance [26]. Also, blaI is able to bind to mecA operator and suppress the transcription of mecA[28].

Back to Top | Article Outline

Staphylococcal cassette chromosome mec

Staphylococcal cassette chromosome mec (SCCmec) is known as a genomic island of unknown origin, as it has the antimicrobial resistance gene mecA[26]. SCCmec also has other genes including ccrA and ccrB, which code the recombinase proteins for incorporation and fission of the SCCmec elements from S. aureus chromosome [26]. SCCmec elements are divided into different types with various mec and ccr genes. These different SCCmec elements cause variation of antimicrobial resistance and different kinds of infections [29]. Types I–III SCCmec are large elements, which possess other antimicrobial resistance genes and are found in community-associated MRSA and hospital-associated MRSA (CDC, 2007). On the contrary, types IV and V are found more in community-associated MRSA [29].

In all types, the integration occurs in the attBscc site near to the origin of the replication of S. aureus[30]. There are three classes of mec as follows: class A mec contains two mecI (transcriptional repressor protein) and mecR1 (signal transduction protein) genes [31], while class B mec includes mecA (with deletion of mecI and some parts of mecR1) and insertion sequence 1272 that are incorporated into the deletion site of mecA. Class C2 contains two copies of insertion sequence 431, mecA (short mecR1) [32]. Thus, type I SCCmec harbours class B mec and ccrA; type II SCCmec has class A mec and ccrB; type III SCCmec contains class A mec and type ccrC; type IV carries class B mec and type ccrB; and type V possess class C mec and type 5 ccr. Therefore, naming of a new SCCmec type is based on ccr complex and class of mec gene.

Back to Top | Article Outline

Public health importance

MRSA is one of the most important antibiotic-resistant pathogens. There is an increasing prevalence of MRSA worldwide. ICUs in the United States showed an increase in MRSA from 36% in 1992 to 64.5% in 2003 [33]. In Europe, the prevalence ranges from 1 to 50%. The morbidity and mortality caused by MRSA infections in the UK increased during the period 1993–2005 (National Statistics, 2007). In 2012, a meta-analysis study in Iran showed that the prevalence of MRSA ranged from 20.4% in Isfahan to 90% in Tehran. Infections by MRSA lead to longer term hospitalization and higher care costs [34].

Surveillance programmes appear to be necessary, such as the European Antibiotic Resistance Surveillance System (EARSS), which monitors the seven most invasive bacteria responsible for antimicrobial resistance (www.earss.rivm.nl). Currently, one of the most crucial issues is the presence of MRSA in the community. In 1993, Australia reported the prevalence of the first MRSA in the community [35]. This was followed by reports of four MRSA in the community, causing paediatric deaths. Now, the prevalence of MRSA in the community is reported worldwide [36], representing a change in the epidemiology of community-associated and hospital-associated MRSA worldwide.

Back to Top | Article Outline

Epidemiology

It is estimated that the range of distribution of MRSA is between 23 and 73% worldwide. MRSA is found to be an important cause of skin and respiratory infections [11]. Malaysia showed a high prevalence of MRSA in 1996 [37]; MRSA were found in the surgical wards and linked to the use of invasive procedures [38].

Back to Top | Article Outline

Europe

It is estimated that the prevalence of MRSA in Europe is around 26% currently. In the SENTRY programme between 1997 and 1999, European countries showed variance in the frequency of prevalence of MRSA (Fig. 2). These surveys revealed greater prevalence in southern Europe [11]. Tiemersma et al. [39] revealed the prevalence of MRSA during the period 1999–2002 in Belgium, Germany, Ireland, Netherlands and the UK. The prevalence of MRSA was varied from 1% in northern Europe to 40% in southern Europe.

Back to Top | Article Outline

Africa

In 1978, the first MRSA was reported in Africa. Thereafter, the occurrence has ranged from 5 to 45% [11,37]. The first isolation of MRSA in Sudan was reported in 1999 [40]. Figure 3 shows the prevalence of MRSA in different African countries.

Back to Top | Article Outline

Asia

The prevalence of MRSA in the Asia Pacific region is greater than in other parts of Asia with a frequency of more than 60%. In Malaysia, the prevalence of MRSA was 17% in 1986 increasing to 40% in 2000 [11]. Figure 4 shows the prevalence of MRSA in the Pacific region.

Back to Top | Article Outline

The United States

In 1974, it was 2%, in 1995, it was 22% and in 2004, it was reported to be 64%. According to the CDC report, 1.5% of the populations of the USA were carriers of MRSA between 2003 and 2004. There was a 50–70% increase in MRSA during the period 2001–2007 in bloodstream infections [41].

Back to Top | Article Outline

Australia

The first report of MRSA in Australia was observed in the 1960s. The first gentamicin-resistant MRSA was found in 1976. Figure 5 shows the prevalence of multiresistant MRSA and nonmultiresistant MRSA in different parts of Australia.

Latest evidence worldwide shows that the highest rate of prevalence (>50%) is in North and South America and Asia. Intermediate rates (25–50%) are observed in China, Australia, Africa and some European countries, including Portugal (49%), Greece (40%), Italy (37%) and Romania (34%). The lowest prevalence was reported in the Netherlands and Scandinavia [42–44]. Very high prevalence of MRSA was reported from Sri Lanka (86.5%), South Korea (77.6%), Vietnam (74.1%), Taiwan (65.0%), Thailand (57.0%) and Hong Kong (56.8%). A lower frequency is found in India (22.6%) [44]. Figure 6 displays the worldwide prevalence of MRSA.

Back to Top | Article Outline

Risk factors

At-risk populations for MRSA include those with HIV, lupus erythematosus, cancer, diabetes and those undergoing transplantation [45]. MRSA is a serious risk to hospitalized patients [46]. People in contact with livestock animals are also at risk for MRSA infections. In 2011, 24.4% of meat and poultry sold in the United States was contaminated with MRSA [47]. Athletes are another group at risk for MRSA associated particularly with fitness centres in the United States.

Back to Top | Article Outline

Treatment

MRSA are resistant to β-lactam antibiotics. The resistance to antibiotics in community-acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA) is different. CA-MRSA are more susceptible to cotrimoxazole, tetracycline and clindamycin, but the choice for treatment of CA-MRSA is vancomycin. HA-MRSA are susceptible to vancomycin [48] as well as some newer antibiotics such as linezolid and daptomycin; both were found to be effective against HA-MRSA and CA-MRSA. Currently, teicoplanin, vancomycin antibiotics are the preferred choices for treatment of MRSA. Unfortunately, new strains of MRSA have appeared that are resistant to vancomycin, known as vancomycin-resistant S. aureus[49]. Linezolid, daptomycin and tigecycline are used for treatment of infections by vancomycin-resistant S. aureus[50].

Back to Top | Article Outline

Acknowledgements

Conflicts of interest

There is no conflict of interest.

Back to Top | Article Outline

References

1. Ryan KJ, Ray CG. Sherris medical microbiology (4th ed.). New York: McGraw Hill; 2004.
2. Corbella X, Dominguez MA, Pujol M, Ayats J, Sendra M, R Ariza Pallares J, Gudiol F. Staphylococcus aureus nasal carriage as a marker for subsequent Staphylococcal infections in intensive care unit patients. Eur J Clin Microbiol Infect Dis 1997; 16:351–357.
3. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5:751–762.
4. Berman DS, Schaefler S, Simberkoff MS, Rahal JJ. Staphylococcus aureus colonization in intravenous drug abusers, dialysis patients, and diabetics. J Infect Dis 1987; 155:829–831.
5. Nguyen MH, Kauffman CA, Goodman RP, Squier C, Arbeit RD, Singh N, et al. Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann Intern Med 1999; 130:221–225.
6. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505–520.
7. Armstrong-Esther CA. Carriage patterns of Staphylococcus aureus in a healthy non-hospital population of adults and children. Ann Hum Biol 1976; 3:221–227.
8. Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 1995; 115:51–60.
9. Cespedes C, Said-Salim B, Miller M, Lo SH, Kreiswirth BN, Gordon RJ, et al. The clonality of Staphylococcus aureus nasal carriage. J Infect Dis 2005; 191:444–452.
10. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of panton-valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128–1132.
11. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the Sentry Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001; 32 (Suppl 2):S114–S132.
12. Eggimann P, Pittet D. Overview of catheter-related infections with special emphasis on prevention based on educational programs. Clin Microbiol Infect 2002; 8:295–309.
13. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13:16–34.table of contents.
14. Demerec M. Production of Staphylococcus strains resistant to various concentrations of penicillin. Proc Natl Acad Sci U S A 1945; 31:16–24.
15. Murray BE, Moellering RC Jr. Patterns and mechanisms of antibiotic resistance. Med Clin North Am 1978; 62:899–923.
16. Jevons MP, Parker MT. The evolution of new hospital strains of Staphylococcus aureus. J Clin Pathol 1964; 17:243–250.
17. Jevons M. ‘Celbenin’ – resistant Staphylococci. BMJ 1961; 1:124–125.
18. Grubb WB. Genetics of MRSA. Rev Med Microbiol 1998; 9:153–162.
19. Delaney JA, Schneider-Lindner V, Brassard P, Suissa S. Mortality after infection with methicillin-resistant Staphylococcus aureus (Mrsa) diagnosed in the community. BMC Med 2008; 6:2.
20. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public health threat. Lancet 2006; 368:874–885.
21. Navarre WW, Schneewind O. Surface proteins of Gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 1999; 63:174–229.
22. Giesbrecht P, Kersten T, Maidhof H, Wecke J. Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Microbiol Mol Biol Rev 1998; 62:1371–1414.
23. Wu SW, de Lencastre H, Tomasz A. Recruitment of the Meca gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus. J Bacteriol 2001; 183:2417–2424.
24. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Staphylococcus cassette chromosome Mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:1549–1555.
25. Ito T, Katayama Y, Hiramatsu K. Cloning and nucleotide sequence determination of the entire Mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrob Agents Chemother 1999; 43:1449–1458.
26. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003; 111:1265–1273.
27. Jensen SO, Lyon BR. Genetics of antimicrobial resistance in Staphylococcus aureus. Future Microbiol 2009; 4:565–582.
28. Berger-Bachi B. Genetic basis of methicillin resistance in Staphylococcus aureus. Cell Mol Life Sci 1999; 56:764–770.
29. Kuo SC, Chiang MC, Lee WS, Chen LY, Wu HS, Yu KW, et al. Comparison of microbiological and clinical characteristics based on Sccmec typing in patients with community-onset meticillin-resistant Staphylococcus aureus (Mrsa) bacteraemia. Int J Antimicrob Agents 2012; 39:22–26.
30. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V Staphylococcal cassette chromosome Mec driven by a novel cassette chromosome recombinase, Ccrc. Antimicrob Agents Chemother 2004; 48:2637–2651.
31. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001; 9:486–493.
32. Boyle-Vavra S, Ereshefsky B, Wang CC, Daum RS. Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette Mec (Sccmec) Type Vt or Sccmec Type Iv. J Clin Microbiol 2005; 43:4719–4730.
33. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin Infect Dis 2006; 42:389–391.
34. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166–174.
35. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25:97–108.
36. Aires de Sousa M, Conceicao T, Simas C, de Lencastre H. Comparison of genetic backgrounds of methicillin-resistant and -susceptible Staphylococcus aureus isolates from Portuguese hospitals and the community. J Clin Microbiol 2005; 43:5150–5157.
37. Zinn CS, Westh H, Rosdahl VT. The Sarisa Study Group: an international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states. Microb Drug Resist 2004; 10:160–168.
38. Rohani M. Antibiotic resistance patterns of bacteria isolated in Malaysian hospitals. Int Med J 1999; 6:47–51.
39. Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, et al. European Antimicrobial Resistance Surveillance System ParticipantsMethicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 2004; 10:1627–1634.
40. Musa HA, Shears P, Khagali A. First report of MRSA from hospitalized patients in sudan. J Hosp Infect 1999; 42:74.
41. Centers for Disease Control and Prevention. MRSA surveillance. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
42. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, Friedrich AW. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med 2010; 7:e1000215.
43. Mejia C, Zurita J, Guzman-Blanco M. Epidemiology and surveillance of methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis 2010; 14 (Suppl 2):S79.
44. Song JH, Hsueh PR, Chung DR, Ko KS, Kang CL, Peck KR. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother 2011; 66:1061–1069.
45. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 2010; 53:914–923.
46. Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352:468–475.
47. Ogata K, Narimatsu H, Suzuki M, Higuchi W, Yamamoto T, Taniguchi H. Commercially distributed meat as a potential vehicle for community-acquired methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol 2012; 78:2797–2802.
48. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid Vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789–1797.
49. Centers for Disease Control and PreventionVancomycin-resistant Staphylococcus aureus – Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
50. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-associated methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050–1058.
Keywords:

methicillin-resistant Staphylococcus aureus; Staphylococcus aureus; vancomycin-resistant Staphylococcus aureus

Copyright © Wolters Kluwer Health, Inc. All rights reserved.